These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 5374472)

  • 21. [Problems and therapy of L-DOPA-induced dyskinesias].
    Völler GW; Deze J; Gundlach U; Muschard F
    Nervenarzt; 1972 Nov; 43(11):584-6. PubMed ID: 4564994
    [No Abstract]   [Full Text] [Related]  

  • 22. [Collateral effects of therapy with L-dopa in Parkinson's disease].
    Gomirato G; Perfetti CC; Ecari U
    Sist Nerv; 1970; 22(2):67-73. PubMed ID: 5504559
    [No Abstract]   [Full Text] [Related]  

  • 23. The effect of L-dopa treatment on the speech of patients with Parkinson's disease.
    Audelman JU; Hoel RL; Lassman FM
    Neurology; 1970 Apr; 20(4):410-1. PubMed ID: 5535064
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of Parkinsonic syndrome with levo-Dopa. Case reports].
    Rosati G; Agnetti V; Mura F; Granieri E
    Minerva Med; 1974 May; 65(33):1811-23. PubMed ID: 4602058
    [No Abstract]   [Full Text] [Related]  

  • 25. L-DOPA in Parkinson's disease. Results of a co-operative study in the Montreal area.
    Mars H; Libman I; Schwartz AM; Gillo-Joffroy L; Barbeau A
    Can Psychiatr Assoc J; 1972 Apr; 17(2):123-31. PubMed ID: 5036506
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment of Parkinson's disease with L-dopa. 77 cases].
    Boudin G; Castaigne P; Lhermitte F; Beck H; Guillard A; Marteau R; Pepin B; Rondot P; Raphy B
    Rev Neurol (Paris); 1970 Feb; 122(2):89-102. PubMed ID: 4931719
    [No Abstract]   [Full Text] [Related]  

  • 27. [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].
    Schneider E; Fischer PA; Jacobi P; Maxion H
    Arch Psychiatr Nervenkr (1970); 1973 Mar; 217(1):95-112. PubMed ID: 4695662
    [No Abstract]   [Full Text] [Related]  

  • 28. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; de Ajuriaguerra J
    Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of parkinsonism with L-dopa (study of 105 patients).
    Klawans HL; Garvin JS
    Dis Nerv Syst; 1969 Nov; 30(11):737-46. PubMed ID: 5359046
    [No Abstract]   [Full Text] [Related]  

  • 30. L-dopa--long-term effects.
    Del Med J; 1971 Aug; 43(8):236. PubMed ID: 5094610
    [No Abstract]   [Full Text] [Related]  

  • 31. Quantitative analysis of the effects of L-dopa on gait in 26 patients with Parkinsonism.
    Peterson CR; Calvert JC; Canzoneri J; Leavitt LA; McCutchen JJ; Schwartz L
    Am J Phys Med; 1972 Aug; 51(4):171-81. PubMed ID: 5052844
    [No Abstract]   [Full Text] [Related]  

  • 32. L-dopa therapy in Parkinson's disease.
    Lipman IJ
    Va Med Mon (1918); 1971 May; 98(5):242-8. PubMed ID: 4931138
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 34. [Considerations on hyperkinesis caused by L-dopa: significance of the biochemical deficit and anatomical deficit].
    Pinelli P
    Arch Psicol Neurol Psichiatr; 1970; 31(5):405-16. PubMed ID: 5502810
    [No Abstract]   [Full Text] [Related]  

  • 35. L-Dopa treatment in Parkinson's Disease.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1970; 4(6):348-69. PubMed ID: 4932969
    [No Abstract]   [Full Text] [Related]  

  • 36. [Indications and results of monoamine treatment in parkinsonian syndromes].
    Boudin G; Pépin B; Guillard A; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1972 Jul; 127(1):79-97. PubMed ID: 4520464
    [No Abstract]   [Full Text] [Related]  

  • 37. [Results of treatment with levodopa and rehabilitative therapy in 10 cases of Parkinson's disease].
    Paciaroni E; Raspa EG
    Sist Nerv; 1970; 22(2):153-61. PubMed ID: 5504554
    [No Abstract]   [Full Text] [Related]  

  • 38. An analysis of L-dopa-induced dyskinesias in 152 cases of Parkinson's disease.
    Mones RJ; Elizan TS; Siegel GJ
    Neurology; 1970 Apr; 20(4):405-6. PubMed ID: 5535050
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of and possible differences in tolerance to L-dopa tablets with different rates of release of the active substance.
    Völler GW; Muschard F
    Acta Neurol Scand; 1974; 50(3):391-3. PubMed ID: 4525037
    [No Abstract]   [Full Text] [Related]  

  • 40. L-dopa. II.
    Br Med J; 1970 Nov; 4(5734):541-2. PubMed ID: 4099003
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.